← Browse by Condition
Medical Condition

facioscapulohumeral muscular dystrophy

Total Trials
2
Recruiting Now
2
Trial Phases
Phase 3

ClinicalMetric tracks all active clinical trials for facioscapulohumeral muscular dystrophy sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — facioscapulohumeral muscular dystrophy Clinical Trials

How many clinical trials are currently recruiting for facioscapulohumeral muscular dystrophy?
ClinicalMetric currently tracks 2 actively recruiting clinical trials for facioscapulohumeral muscular dystrophy, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 2. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for facioscapulohumeral muscular dystrophy?
facioscapulohumeral muscular dystrophy research spans Phase 3 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a facioscapulohumeral muscular dystrophy clinical trial?
Eligibility criteria for facioscapulohumeral muscular dystrophy trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 3
1
Top Sponsors
Avidity Biosciences, Inc. 1 trial
University of Rochester 1 trial

Recruiting Clinical Trials

NCT07038200 Phase 3
Recruiting
A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD
Enrollment
200 pts
Location
United States, Canad...
Sponsor
Avidity Biosciences, Inc.
View Trial →
NCT00082108
Recruiting
Myotonic Dystrophy and Facioscapulohumeral Muscular Dystrophy Registry
Enrollment
3,000 pts
Location
United States
Sponsor
University of Rochester
View Trial →

Related Conditions

fshd (1) fshd facioscapulohumeral muscular dystrophy (1) fshd1 (1) fshd2 (1) fascioscapulohumeral muscular dystrophy (1) fascioscapulohumeral muscular dystrophy type 1 (1) fascioscapulohumeral muscular dystrophy type 2 (1) facioscapulohumeral muscular dystrophy 1 (1) facioscapulohumeral dystrophy (1) facio scapulo humeral dystrophy (1) facioscapulohumeral muscular dystrophy 2 (1) facioscapulohumeral muscular dystrophy type 1 fshd1 (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology